Loading
Puma Biotechnology, Inc. Stock: price and insider trades · United States
Puma Biotechnology, Inc.: what insiders have been doing
Puma Biotechnology, Inc. is a Healthcare & Pharma company based in Los Angeles, United States. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 25 filings were filed, from 15 insiders.
No insider bought on the market over the period, while 6 insiders filed 9 sales totalling €1.1M. No amount is published for 1 filing, which the totals therefore leave out. Cesano Alessandra filed the largest sale, €489k, on 16 September 2026, which represents 0.12% of the company's market value.
With 25 filings in twelve months, the company is more active than the median of 19 filings across the 5,813 companies we follow on the same exchange. Our records for Puma Biotechnology, Inc. go back to 2021, with no purchases and 138 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 228.4 m USD of revenue and 31.1 m USD of net income.
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
202
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€5M
138 ops. · all time
Who traded when
BuySaleAlan H. Auerbach4 sales
Douglas M. Hunt4 sales
Maximo F. Nougues4 sales
Alessandra Cesano3 sales
Allison Dorval2 sales
Wilson Troy Edward2 sales
+5 other insiders
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,916 of 24,148 companies
75.8
score / 100
Value69
Quality83
FCF yld8.2%
Earn yld6.1%
EV/EBITDA10.0x
ROE22%
Gross mgn75%
Net mgn14%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.83
Analyst consensus
1 analysts3.00/5
US$6.00Target US$6.00(-39%)US$6.00
Income statement
RevenueUS$228.4M
Gross profitUS$170.2M75% margin
EBITDAUS$53.3M23% margin
Net incomeUS$31.1M11.6% margin
Valuation
PER (trailing)19.3x
PER (forward)26.4x
P/Book3.6x
Beta1.21
Balance sheet & cash
Market capUS$507.4M
Total debtUS$28.5M
Free Cash FlowUS$41.7M
Debt / Equity3%
Profitability & ownership
ROE22.0%
ROA9.8%
% insiders15.4%
% institutions75.6%
Last declaration on 16 September 2026
Declarations202 total
50,000 shares@ US$2.930.030% mcap10.4% of flowCommon StockSEC:0001437749-26-030593:0
62,150 shares@ US$9.1230.12% mcap40.2% of flowCommon StockSEC:0001437749-26-030593:1
62,150 shares@ US$9.100.12% mcap40.1% of flowCommonSEC144:0001959173-26-006918
5,000 shares@ US$9.100.0093% mcap6.4% of flowCommonSEC144:0001959173-26-006917
8,460 shares@ US$8.2630.015% mcap18.1% of flowCommon StockSEC:0001437749-26-023078:0
44,058 shares@ US$8.2630.076% mcap7.7% of flowCommon StockSEC:0001437749-26-023079:0
9,386 shares@ US$8.2630.016% mcap14.8% of flowCommon StockSEC:0001437749-26-023077:0
44,058 shares@ US$8.26280.076% mcap7.7% of flowCommonSEC144:0001959173-26-005126
8,460 shares@ US$8.26280.015% mcap18.1% of flowCommonSEC144:0001959173-26-005123
9,386 shares@ US$8.26280.016% mcap14.8% of flowCommonSEC144:0001959173-26-005121
27,000 sharesCommon StockSEC:0001437749-26-020702:0
27,000 sharesCommon StockSEC:0001437749-26-020703:0
11,610 sharesCommon StockSEC:0001437749-26-020703:1
11,610 shares@ US$7.260.021% mcap42.0% of flowCommonSEC144:0001959173-26-004588
22,000 shares@ US$7.260.039% mcap21.8% of flowCommonSEC144:0001959173-26-004589
10,800 shares@ US$7.260.019% mcap11.0% of flowCommonSEC144:0001959173-26-004584
8,100 shares@ US$7.260.015% mcap29.8% of flowCommonSEC144:0001959173-26-004586
27,000 shares@ US$7.260.048% mcap19.6% of flowCommonSEC144:0001959173-26-004590
159,778 shares0Common StockSEC:0001437749-26-004948:0
49,394 shares0Common StockSEC:0001437749-26-004947:0
46,739 shares0Common StockSEC:0001437749-26-004946:0
16,938 shares@ US$5.8442.0% of flowCommon StockSEC:0001437749-26-000924:0
4,540 shares@ US$5.8444.9% of flowCommon StockSEC:0001437749-26-000921:0
3,973 shares@ US$5.8445.9% of flowCommon StockSEC:0001437749-26-000922:0
20,000 shares@ US$4.861420.0% of flowCommon StockSEC:0001437749-25-034874:0
25 of 202 declarations
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker PBYI. Headquartered in Los Angeles, California, in the United States, the company focuses on acquiring, developing, and commercializing novel cancer therapeutics. Its strategy is that of a specialty oncology biotech rather than a broad diversified pharmaceutical group: Puma tends to license or in-license assets with clinical precedent, advance them through development, and then build commercial value through focused execution. The company’s current corporate form traces back to 2010, and founder Alan H. Auerbach has remained central to the business since inception. ([pumabiotechnology.com](https://www.pumabiotechnology.com/about/overview.html?utm_source=openai))
Puma’s core commercial asset is NERLYNX® (neratinib), an oral oncology therapy that remains the company’s primary revenue driver. Recent company disclosures show that product revenue is derived overwhelmingly from NERLYNX sales, supplemented by royalty income from select international arrangements. In addition to maintaining the NERLYNX franchise, Puma has added a second growth pillar with alisertib, an asset in-licensed from Takeda in 2022. The drug is now being advanced in clinical programs such as ALISCA™-Breast1 and ALISCA™-Lung1, which target chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer and extensive-stage small cell lung cancer. For investors, that is an important point: Puma remains highly dependent on one marketed product, but it is also working to expand its pipeline and reduce single-asset concentration over time. ([investor.pumabiotechnology.com](https://investor.pumabiotechnology.com/news-releases/news-release-details/puma-biotechnology-reports-fourth-quarter-and-full-year-2025))
Read moreShow less
From a competitive standpoint, Puma occupies a niche position in targeted oncology. NERLYNX is established in HER2-related breast cancer care, where it competes in a sophisticated but crowded treatment landscape. Puma does not have the scale of a major global pharma company; instead, its edge lies in specialization, a commercialized revenue base, and disciplined capital allocation. Geographically, the business is still primarily U.S.-anchored, although the company also benefits from international sublicensing and royalty streams, including activity referenced in recent disclosures from Asia. ([investor.pumabiotechnology.com](https://investor.pumabiotechnology.com/news-releases/news-release-details/puma-biotechnology-reports-fourth-quarter-and-full-year-2025))
Recent milestones have been constructive. Puma reported 2025 results showing a third consecutive year of profitability, total revenue of $228.4 million, and positive operating cash flow. Management also guided to continued profitability in 2026 and highlighted several clinical readouts for alisertib expected over the next 12 months. For international investors monitoring U.S. healthcare names, PBYI presents a mix of commercial-stage stability, product concentration risk, and clinical upside tied to its oncology pipeline. ([investor.pumabiotechnology.com](https://investor.pumabiotechnology.com/news-releases/news-release-details/puma-biotechnology-reports-fourth-quarter-and-full-year-2025))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
